Hao Chang

Hao Chang

Auto-generated profile, based on publicly available information

Hao Chang

University of Wisconsin-Madison 1 Department of Dermatology Madison, WI 53705

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Development
Verified
Journal Article
Closed access
PDF file
BDBo Dong
Bo Dong
SVSamantha Vold
Samantha Vold
COCristina Olvera-Jaramillo
Cristina Olvera-Jaramillo
HCHao Chang
Hao Chang
The orientation of mouse hair follicles is controlled by the planar cell polarity (PCP) pathway. Mutations in PCP genes result in two categories of hair misorientation phenotype, randomly oriented and vertically oriented to the skin surface. Here we demonstrate that the randomly oriented hair phenotype in Frizzled 6 (Fzd6) is a partial loss of the polarity, due to the functional redundancy of another closely related Frizzled gene, Fzd3. Double knockout of Fzd3 and Fzd6 globally, or only in the skin, lead to vertically oriented hair follicles and a total loss of anterior-posterior polarity. Furthermore, we provide evidence that, contrary to the prevailing model, asymmetric localization of the Fzd6 protein is not observed in skin epithelial cells. Through transcriptome analyses and in vitro studies, we show collagen triple helix repeat containing 1 (Cthrc1) as a potential downstream effector of Fzd6, but not Fzd3. Cthrc1 binds directly to the extracellular domains of Fzd3 and Fzd6 to enhance the Wnt/PCP signaling. These results suggest that Fzd3 and Fzd6 play a redundant role in controlling the polarity of developing skin, but through non-identical mechanisms.

8 November 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
BDBo Dong
Bo Dong
LSLaura Simonson
Laura Simonson
SVSamantha Vold
Samantha Vold
EOEthan Oldham
Ethan Oldham
LBLillian Barten
Lillian Barten
HCHao Chang
Hao Chang

3 August 2020 in Developmental Biology
Verified
Journal Article
Closed access
LSLaura Simonson
Laura Simonson
SVSamantha Vold
Samantha Vold
CMColton Mowers
Colton Mowers
RMRandall J. Massey
Randall J. Massey
IOIrene M. Ong
Irene M. Ong
HCHao Chang
Hao Chang

30 May 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
CSChandra Singh
Chandra Singh
GCGagan Chhabra
Gagan Chhabra
APArth Patel
Arth Patel
HCHao Chang
Hao Chang
Nihal AhmadNihal Ahmad
Nihal Ahmad
Studies have suggested an important role of the trace element zinc (Zn) in prostate biology and functions. Zn has been shown to exist in very high concentrations in the healthy prostate and is important for several prostatic functions. In prostate cancer (PCa), Zn levels are significantly decreased and inversely correlated with disease progression. Ideally, restoration of adequate Zn levels in premalignant/malignant prostate cells could abort prostate malignancy. However, studies have shown that Zn supplementation is not an efficient way to significantly increase Zn concentrations in PCa. Based on a limited number of investigations, the reason for the lower levels of Zn in PCa is believed to be the dysregulation of Zn transporters (especially ZIP and ZnT family of proteins), metallothioneins (for storing and releasing Zn), and their regulators (e.g., Zn finger transcription factor RREB1). Interestingly, the level of Zn in cells has been shown to be modulated by naturally occurring dietary phytochemicals. In this review, we discussed the effect of selected phytochemicals (quercetin, resveratrol, epigallocatechin-3-gallate and curcumin) on Zn functioning and proposes that Zn in combination with specific dietary phytochemicals may lead to enhanced Zn bioaccumulation in the prostate, and therefore, may inhibit PCa.

18 May 2017 in IUBMB Life
Verified
Journal Article
Closed access
PDF file
HCHao Chang
Hao Chang

16 July 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
ZZZhen Zhang
Zhen Zhang
CLChunrong Li
Chunrong Li
NHNina J. Hawkins
Nina J. Hawkins
RMRamesh Mudududdla
Ramesh Mudududdla
YNYiming Nie
Yiming Nie
WTWeiping Tang
Weiping Tang
Receptor-interacting protein kinase 1 (RIPK1) is a threonine/serine kinase that serves as a critical regulator of immune responses and cell death pathways, functioning through both its kinase activity and nonenzymatic scaffolding function. The scaffolding function of RIPK1 contributes to both intrinsic and extrinsic resistance to immune checkpoint blockades (ICBs), making it a compelling therapeutic target for cancer treatment. Recent studies have highlighted RIPK1's potential as a key modulator for improving the efficacy of immune-stimulatory therapies, such as ICBs and X-ray radiotherapy (XRT). In this study, we have developed a highly potent and selective RIPK1 degrader. When combined with XRT, the degrader significantly suppressed tumor growth, achieving enhanced therapeutic efficacy without apparent adverse effects. In contrast, the RIPK1 inhibitor showed no notable therapeutic effect. These findings underscore the potential of targeting RIPK1 degradation, specifically its nonenzymatic function, as a novel strategy to augment the effects of radiotherapy.